Octagon Research Solutions Inc. has been named to Deloitte?s prestigious Fast 50 Program for Greater Philadelphia, a ranking of the 50 fastest growing technology, media, telecommunications and life sciences companies in the area by Deloitte LLP, one of the nation?s leading professional services organizations.
Octagon Research Solutions Inc. Ranked NUmber 20 in Deloitte’s Fast 50 Program for Greater Philadelphia
(WAYNE, PA, November 17, 2008) -Octagon Research Solutions Inc. has been named to Deloitte’s prestigious Fast 50 Program for Greater Philadelphia, a ranking of the 50 fastest growing technology, media, telecommunications and life sciences companies in the area by Deloitte LLP, one of the nation’s leading professional services organizations. Rankings are based on the percentage revenue growth over five years from 2003–2007.
“It’s a great honor to be recognized for three consecutive years on the Deloitte Technology Fast 50,” stated Jim Walker, CEO and chairman, Octagon Research Solutions, Inc. “Each year, we raise the bar by staying committed to our vision of revolutionizing the industry and providing our clients with a variety of innovative products and services that address emerging industry standards. It’s because of this shared vision and the entrepreneurial approach of both my senior staff and employees that we are able to grow exponentially within the industry,” continued Mr. Walker.
Octagon’s increase in revenues of 314 percent from 2003 to 2007 resulted in a 20 ranking in the Fast 50 for Greater Philadelphia. The average increase in revenues among companies who made the Fast 50 for this region was 773 percent.
The Greater Philadelphia Fast 50 program is presented by Deloitte and sponsored by Fragomen, Del Rey, Bernsen & Loewy, LLP, The Judge Group, and UK Trade & Investment.
To qualify for the Fast 50, companies must have had operating revenues of at least $50,000 in 2003 and $5,000,000 in 2007, be headquartered in North America, and be a company that owns proprietary technology or proprietary intellectual property that contributes to a significant portion of the company’s operating revenues; or devotes a significant proportion of revenues to the research and development of technology. Using other companies’ technology or intellectual property in a unique way does not qualify.
Winners of the regional Fast 50 programs in the United States and Canada are automatically entered in Deloitte’s Fast 500 program, which ranks North America’s top 500 fastest growing technology, media, telecommunications, and life sciences companies.
For more information on Deloitte’s Fast 50 or Fast 500 programs, visit www.fast500.com.
About Octagon Research Solutions, Inc.
Octagon is a pioneer and leading provider of breakthrough software and services to the life sciences industry. Octagon’s eCTD and CDISC solutions provide the people, process and technology required to optimize drug development from data collection to submission. Our regulatory, clinical, process and software offerings provide a unique combination of deep domain knowledge, cross-functional electronic submission expertise, a holistic process approach, and integrated solutions. Octagon is headquartered in Wayne, PA, with European headquarters in Berkhamsted, UK. Octagon’s EDC Operations are located in Mountain View, CA. For more information please visit www.octagonresearch.com
About Deloitte
Deloitte refers to one or more of Deloitte Touche Tohmatsu, a Swiss Verein, and its network of member firms, each of which is a legally separate and independent entity. Please see www.deloitte.com/about for a detailed description of the legal structure of Deloitte Touche Tohmatsu and its member firms. Please see www.deloitte.com/us/about for a detailed description of the legal structure of Deloitte LLP and its subsidiaries.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.